Suppr超能文献

肾脏原发性淀粉样变性

Primary amyloidosis of the kidney.

作者信息

Shafique Shahzad, Wetmore James, Almehmi Ammar

机构信息

Division of Nephrology, Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS, USA.

出版信息

W V Med J. 2010 Jan-Feb;106(1):22-4.

Abstract

Primary (AL) amyloidosis is a lethal form of plasma cell dyscrasia characterized by monoclonal immunoglobulin light chain deposition causing organ dysfunction. The median age for AL amyloidosis incidence is 64 years, with less than 1% occurring under age 40. The kidney is frequently involved in AL amyloidosis; nephrotic syndrome and/or end stage renal disease (ESRD) occur at presentation in about two-thirds of the patients. High-dose melphalan with autologous peripheral blood stem cell transplantation (ASCT) is an effective treatment for systemic primary amyloidosis. This procedure is, however, associated with substantial toxicity and mortality, particularly if the heart is involved. Here we report a case of primary AL amyloidosis in a 40 year old male who presented with a single-organ involvement (e.g.: kidney) that progressed rapidly to ESRD. Melphalan and ASCT resulted in a complete hematological recovery. This case highlights the possibility that single organ involvement and young age may be associated with better prognosis and improved survival.

摘要

原发性(AL)淀粉样变性是浆细胞发育异常的一种致命形式,其特征为单克隆免疫球蛋白轻链沉积导致器官功能障碍。AL淀粉样变性发病的中位年龄为64岁,40岁以下发病者不到1%。肾脏常受累于AL淀粉样变性;约三分之二的患者在就诊时出现肾病综合征和/或终末期肾病(ESRD)。大剂量美法仑联合自体外周血干细胞移植(ASCT)是治疗系统性原发性淀粉样变性的有效方法。然而,该 procedure 伴有严重的毒性和死亡率,尤其是在心脏受累的情况下。我们在此报告一例40岁男性原发性AL淀粉样变性病例,该患者表现为单一器官受累(如肾脏),并迅速进展为ESRD。美法仑和ASCT导致血液学完全缓解。该病例突出了单一器官受累和年轻可能与更好的预后及生存率提高相关的可能性。 (注:原文中“this procedure”未明确指出具体是什么操作,根据前文推测可能是指“High-dose melphalan with autologous peripheral blood stem cell transplantation (ASCT)”,翻译时保留了英文表述。)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验